Scopolamine is a competitive antagonist of the M1 muscarinic acetylcholine receptors and widely used to induce cognitive decline in animal models by exerting its anticholinergic and ant muscarinic effects (for review, Klinkenberg&Blokland, 2010). It is used as human medication in e.g. motion sickness. The scopolamine model has recently been described for use in a human cognition models investigating potential cognitive enhancers in healthy volunteers.
SynAging has implemented and validated an in vivo model of scopolamine induced reversible amnesia using mice in a Y-maze assay. Scopolamine impairs several behavioral processes and in particular short-term memory. The model is used extensively for preclinical testing of new compounds with potential to improve cognitive impairment.
Acute i.p. administration of scopolamine induces a fast and reversible decrease of the working memory performances in mice monitored by decreased natural alternation behavior in the Y-maze assay: normal mice alternate between exploring multiple arms in a maze, whereas scopolamine challenged mice show complete lack of orientation. The SynAging’s team has validated this mouse model, as well as computerized the read-out used, demonstrating that short-term memory deficits induced by scopolamine arereadily reverted by reference drugs such as donepezil (Aricept® used for the symptomatic treatment of Alzheimer’s dementia), rolipram (an inhibitors of phosphodiesterase 4) and RO4491533, a negative allosteric modulator of mGluR2/3.
We are offering this model for the evaluation of your compounds on a competitive fee-for-service basis, providing excellent reproducibility and highly significant results for established reference compounds.